Cryofocus Medtech (Shanghai) (HKG:6922) has obtained approval for its Malignant Stenosis Cryoablation System from China's National Medical Products Administration, a Thursday filing with the Hong Kong bourse said.

The product is a self-developed cryoablation system indicated to ablate malignant airway tumor tissue and reduce the frequency of airway restenosis, according to the medical device company.

Price (HKD): $4.83, Change: $-0.15, Percent Change: -3.01%